HCC
MCID: HPT023
MIFTS: 96

Hepatocellular Carcinoma (HCC)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hepatocellular Carcinoma

MalaCards integrated aliases for Hepatocellular Carcinoma:

Name: Hepatocellular Carcinoma 57 11 58 75 73 28 53 5 14 36 16
Liver Cancer 57 11 73 41 14 33
Primary Liver Cancer 11 19 14 33
Malignant Neoplasm of Liver 11 71 33
Liver Neoplasms 75 43 71
Hepatoma 57 11 73
Hcc 57 58 73
Rare Tumor of Liver and Intrahepatic Biliary Tract 19 58
Primary Malignant Neoplasm of Liver 11 71
Hepatoblastoma, Somatic 57 12
Cancer, Hepatocellular 57 38
Liver Cell Carcinoma 57 73
Hepatic Cancer 11 53
Lcc 57 73
Malignant Neoplasm of Liver, Not Specified As Primary or Secondary 11
Hepatocellular Carcinoma, Childhood Type, Somatic 57
Non-Resectable Primary Hepatic Malignant Neoplasm 11
Liver and Intrahepatic Biliary Tract Carcinoma 71
Resectable Malignant Neoplasm of the Liver 11
Adult Primary Hepatocellular Carcinoma 71
Resectable Malignant Neoplasm of Liver 11
Malignant Neoplasm of Liver, Primary 11
Hepatocellular Carcinoma, Somatic 57
Malignant Hepato-Biliary Neoplasm 11
Primary Malignant Liver Neoplasm 19
Malignant Hepatobiliary Neoplasm 71
Hepatocellular Cancer, Somatic 57
Rare Tumor of Liver and Ibt 58
Primary Tumor of the Liver 19
Carcinoma, Hepatocellular 43
Malignant Tumor of Liver 11
Malignant Hepatic Tumour 33
Primary Liver Carcinoma 19
Primary Cancer of Liver 19
Malignant Liver Tumour 33
Hepatocellular Cancer 73
Neoplasm of the Liver 5
Ca Liver - Primary 11
Carcinoma of Liver 33
Neoplasm of Liver 11
Hepatic Neoplasm 11
Liver Carcinoma 71
Hepatoblastoma 71
Liver Neoplasm 16
Hepatomas 14

Characteristics:


Inheritance:

Somatic mutation 57

Prevelance:

1-9/100000 (United States, France, United Kingdom, Germany, Spain, Italy, Canada, Oceania, Europe, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Norway, Portugal, Slovakia, Switzerland, Netherlands) 1-5/10000 (Europe, Greece, Latin America, China, Japan, Korea, Republic of, Africa) 6-9/10000 (Mongolia) 1-9/1000000 (Poland) 58

Age Of Onset:

All ages 58

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
genetic heterogeneity


Classifications:

Orphanet: 58  
Rare hepatic diseases


Summaries for Hepatocellular Carcinoma

MedlinePlus: 41 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Primary liver cancer starts in the liver. Metastatic liver cancer starts somewhere else and spreads to your liver. Risk factors for primary liver cancer include : Having hepatitis B or C Heavy alcohol use Having cirrhosis, or scarring of the liver Having hemochromatosis, an iron storage disease Obesity and diabetes Symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. However, you may not have symptoms until the cancer is advanced. This makes it harder to treat. Doctors use tests that examine the liver and the blood to diagnose liver cancer. Treatment options include surgery, radiation, chemotherapy, or liver transplantation. NIH: National Cancer Institute

MalaCards based summary: Hepatocellular Carcinoma, also known as liver cancer, is related to colorectal cancer and adult hepatocellular carcinoma, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Hepatocellular Carcinoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Alzheimer's disease and miRNA effects and ncRNAs involved in Wnt signaling in hepatocellular carcinoma. The drugs Sargramostim and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and bone marrow, and related phenotypes are hepatomegaly and portal hypertension

OMIM®: 57 Hepatocellular carcinoma is the major histologic type of malignant primary liver neoplasm. It is the fifth most common cancer and the third most common cause of death from cancer worldwide. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. Hepatoblastomas comprise 1 to 2% of all malignant neoplasms of childhood, most often occurring in children under 3 years of age. Hepatoblastomas are thought to be derived from undifferentiated hepatocytes (Taniguchi et al., 2002). (114550) (Updated 08-Dec-2022)

GARD: 19 A rare carcinoma of the liver characterized by one to several or many nodules occurring anywhere within the liver, composed of neoplastic epithelial cells with hepatocellular differentiation. The vast majority of tumors are associated with chronic liver disease (such as hepatitis B or C, or steatohepatitis) or exposure to a variety of exogenous agents. Patients may present with signs and symptoms related to the tumor, as well as to the underlying condition. Common manifestations include right upper quadrant abdominal pain, weight loss, hepatosplenomegaly, jaundice, and ascites. Symptomatic tumors generally have poor prognosis.

UniProtKB/Swiss-Prot: 73 A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.

Orphanet: 58 Hepatocellular carcinoma is a primary hepatic cancer derived from well-differentiated hepatocytes. It is more frequent in adults than in childhood. Symptoms are hepatic mass, abdominal pain and, in advanced stages, jaundice, cachexia and liver failure.

Disease Ontology 11 Hepatocellular carcinoma: A liver carcinoma that has material basis in undifferentiated hepatocytes and located in the liver.

Liver cancer: A hepatobiliary system cancer that is located in the liver.

Wikipedia: 75 Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults and is... more...

Related Diseases for Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2025)
# Related Disease Score Top Affiliating Genes
1 colorectal cancer 34.3 TP53 TERT PIK3CA PDGFRL MIR34A MIR224
2 adult hepatocellular carcinoma 34.2 TP53 PIK3CA PDGFRL CTNNB1 CASP8 AXIN1
3 breast cancer 34.1 TP53 TERT PIK3CA MIR34A MIR221 MIR21
4 lung cancer 33.9 TP53 TERT PIK3CA MIR34A MIR224 MIR221
5 esophageal cancer 33.8 TP53 TERT PIK3CA MIR34A MIR221 MIR21
6 type 2 diabetes mellitus 33.7 TP53 TERT PIK3CA MIR34A MIR224 MIR221
7 cholangiocarcinoma 33.7 TP53 TERT PIK3CA MIR21 MIR200B MET
8 gastric cancer 33.6 TP53 TERT PIK3CA MIR34A MIR221 MIR21
9 pancreatic cancer 33.6 TP53 TERT PIK3CA MIR34A MIR221 MIR21
10 non-alcoholic fatty liver disease 33.6 MIR34A MIR21 MIR200B MIR17 MIR122 ALB
11 prostate cancer 33.6 TP53 TERT PIK3CA MIR34A MIR224 MIR221
12 liver disease 33.6 MIR34A MIR21 MIR155 MIR122 ALB
13 hepatitis b 33.6 PIK3CA MIR21 MIR17 ALB
14 renal cell carcinoma, nonpapillary 33.5 TP53 PIK3CA MIR34A MIR224 MIR221 MIR21
15 melanoma 33.4 TP53 TERT PIK3CA MIR34A MIR224 MIR221
16 ovarian cancer 33.4 TP53 TERT PIK3CA MIR34A MIR221 MIR21
17 fatty liver disease 33.2 MIR34A MIR21 MIR155 MIR122
18 leukemia, acute myeloid 33.2 TP53 TERT PIK3CA MIR34A MIR221 MIR21
19 diabetes mellitus 33.2 TP53 MIR34A MIR21 MIR17 MIR155 MIR122
20 hemochromatosis, type 1 33.2 MIR34A MIR122 AXIN1 ALB
21 brain cancer 33.1 TP53 TERT PIK3CA MIR34A MIR224 MIR221
22 bile duct cancer 33.1 TP53 PIK3CA MIR221 MIR21 MIR17 MET
23 non-alcoholic steatohepatitis 33.1 MIR34A MIR21 MIR122 ALB
24 lung cancer susceptibility 3 33.1 TP53 TERT PIK3CA MIR21 MIR200B MIR17
25 body mass index quantitative trait locus 11 33.1 TP53 MIR34A MIR221 MIR21 MIR18A MIR17
26 lymphoma, non-hodgkin, familial 33.1 TP53 PIK3CA MIR34A MIR224 MIR21 MIR200B
27 glioblastoma 33.0 TP53 TERT PIK3CA MIR34A MIR221 MIR21
28 hypertension, essential 32.9 TP53 MIR34A MIR221 MIR21 MIR17 MIR155
29 squamous cell carcinoma, head and neck 32.8 TP53 PIK3CA MIR221 MIR21 MIR200B MIR18A
30 intrahepatic cholangiocarcinoma 32.8 TP53 MIR17 CTNNB1 ALB
31 hepatoblastoma 32.8 TP53 TERT MET CTNNB1 APC
32 hematologic cancer 32.8 MIR34A MIR221 MIR21 MIR200B MIR18A MIR17
33 medulloblastoma 32.7 TP53 TERT PIK3CA MIR34A MIR221 MIR18A
34 neuroblastoma 32.7 TP53 TERT PIK3CA MIR34A MIR221 MIR21
35 endometrial cancer 32.7 TP53 TERT PIK3CA MIR21 MIR200B MET
36 adenocarcinoma 32.7 TP53 PIK3CA MET CTNNB1 APC
37 adenoma 32.7 TP53 PIK3CA CTNNB1 APC
38 cervical cancer 32.7 TP53 TERT PIK3CA MIR34A MIR224 MIR221
39 gastrointestinal system disease 32.7 MIR34A MIR224 MIR221 MIR21 MIR200B MIR18A
40 colonic benign neoplasm 32.7 TP53 PIK3CA MIR21 MIR18A CTNNB1 AXIN1
41 bladder cancer 32.7 TP53 TERT PIK3CA MIR221 MIR21 MIR17
42 head and neck cancer 32.6 TP53 PIK3CA MIR34A MIR224 MIR221 MIR21
43 leukemia, chronic lymphocytic 32.6 TP53 MIR34A MIR224 MIR221 MIR21 MIR200B
44 nasopharyngeal carcinoma 32.6 TP53 TERT PIK3CA MIR21 MIR18A MIR17
45 peripheral nervous system disease 32.6 TP53 TERT MIR34A MIR21 MIR200B MIR17
46 skin disease 32.6 TP53 TERT PIK3CA MIR34A MIR224 MIR221
47 lymphatic system disease 32.5 TP53 MIR34A MIR224 MIR221 MIR21 MIR200B
48 kidney cancer 32.5 TP53 PIK3CA MIR21 MIR200B MIR17 MIR122
49 gallbladder cancer 32.5 TP53 TERT PIK3CA MIR17 CTNNB1 APC
50 immune deficiency disease 32.4 MIR34A MIR221 MIR21 MIR17 MIR155 MIR122

Comorbidity relations with Hepatocellular Carcinoma via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Alcoholic Liver Cirrhosis Deficiency Anemia
Hepatic Encephalopathy Intrahepatic Gall Duct Cancer
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatocellular Carcinoma:



Diseases related to Hepatocellular Carcinoma

Symptoms & Phenotypes for Hepatocellular Carcinoma

Human phenotypes related to Hepatocellular Carcinoma:

58 30 (show top 50) (show all 51)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hepatomegaly 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002240
2 portal hypertension 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001409
3 abdominal pain 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002027
4 hyperbilirubinemia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002904
5 hypoalbuminemia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003073
6 type ii diabetes mellitus 58 30 Frequent (33%) Frequent (79-30%)
HP:0005978
7 elevated hepatic transaminase 58 30 Frequent (33%) Frequent (79-30%)
HP:0002910
8 anorexia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002039
9 weight loss 58 30 Frequent (33%) Frequent (79-30%)
HP:0001824
10 esophageal varix 58 30 Frequent (33%) Frequent (79-30%)
HP:0002040
11 venous insufficiency 58 30 Frequent (33%) Frequent (79-30%)
HP:0005293
12 abdominal distention 58 30 Frequent (33%) Frequent (79-30%)
HP:0003270
13 epigastric pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0410019
14 abnormal rectum morphology 30 Frequent (33%) HP:0002034
15 hypokalemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002900
16 fatigue 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012378
17 fever 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001945
18 hypoglycemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001943
19 anemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001903
20 ascites 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001541
21 thrombocytopenia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001873
22 jaundice 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000952
23 dyspnea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002094
24 neoplasm 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002664
25 hyponatremia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002902
26 hypercalcemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003072
27 internal hemorrhage 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011029
28 polycythemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001901
29 bone pain 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002653
30 poor appetite 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0004396
31 diarrhea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002014
32 pedal edema 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010741
33 hepatic encephalopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002480
34 thrombocytosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001894
35 metabolic alkalosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0200114
36 hepatic necrosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002605
37 anasarca 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012050
38 hemobilia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100762
39 emotional lability 30 Occasional (7.5%) HP:0000712
40 hypotension 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002615
41 liver abscess 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100523
42 budd-chiari syndrome 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002639
43 abnormality of the liver 58 Very frequent (99-80%)
44 hepatocellular carcinoma 30 HP:0001402
45 abnormality of the hepatic vasculature 58 Very frequent (99-80%)
46 abnormality of the rectum 58 Frequent (79-30%)
47 mood changes 58 Occasional (29-5%)
48 abnormality of glycoprotein metabolism 58 Occasional (29-5%)
49 constitutional symptom 58 Occasional (29-5%)
50 micronodular cirrhosis 30 HP:0001413

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Abdomen Liver:
hepatocellular carcinoma
micronodular cirrhosis
subacute progressive viral hepatitis

Laboratory Abnormalities:
often integrated hbv sequences in hepatocellular carcinomas

Neoplasia:
primary liver cancer

Clinical features from OMIM®:

114550 (Updated 08-Dec-2022)

UMLS symptoms related to Hepatocellular Carcinoma:


nausea and vomiting; constipation; fever; abdominal pain; diarrhea; hepatosplenomegaly; dyspepsia; icterus; heartburn; gastrointestinal gas; malaise

MGI Mouse Phenotypes related to Hepatocellular Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 10.14 ALB APC AXIN1 CTNNB1 IGF2R MET
2 neoplasm MP:0002006 10.13 ALB APC CASP8 CTNNB1 MET MIR122
3 endocrine/exocrine gland MP:0005379 10.03 ALB APC CASP8 CTNNB1 IGF2R MET
4 renal/urinary system MP:0005367 10.02 ALB APC AXIN1 CASP8 CTNNB1 IGF2R
5 liver/biliary system MP:0005370 9.97 ALB APC CASP8 CTNNB1 IGF2R MET
6 digestive/alimentary MP:0005381 9.81 ALB APC AXIN1 CTNNB1 MET MIR155
7 cellular MP:0005384 9.73 ALB APC AXIN1 CASP8 CTNNB1 IGF2R
8 respiratory system MP:0005388 9.28 AXIN1 CASP8 CTNNB1 IGF2R MET MIR155

Drugs & Therapeutics for Hepatocellular Carcinoma

Drugs for Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 637)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sargramostim Approved, Investigational Phase 4 123774-72-1
2
Lenograstim Approved, Investigational Phase 4 135968-09-1
3
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
4
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
5
Cefazolin Approved Phase 4 25953-19-9 33255
6
Acetic acid Approved Phase 4 64-19-7 176
7
Nadolol Approved Phase 4 42200-33-9 39147
8
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
9
Iodine Approved, Investigational Phase 4 7553-56-2 807
10
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
11
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 77335690 67683363
12
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
13
Difluocortolone Approved, Investigational, Withdrawn Phase 4 2607-06-9 14445457 11954369
14
Norepinephrine Approved Phase 4 51-41-2 439260
15
Nicotine Approved Phase 4 54-11-5 942 89594
16
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
17
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
18
Atropine Approved, Vet_approved Phase 4 101-31-5, 5908-99-6, 51-55-8 3661 154417 174174
19
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
20
Povidone-iodine Approved Phase 4 25655-41-8
21
Povidone K30 Approved, Experimental, Withdrawn Phase 4 9003-39-8 6917 131751496
22
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 4 62-33-9, 60-00-4 6049
23
Pentetic acid Approved Phase 4 67-43-6
24
Iron Approved Phase 4 7439-89-6 29936
25
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
26
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
27
Reviparin Approved, Investigational Phase 4 9041-08-1
28
Nitric Oxide Approved Phase 4 10102-43-9 145068
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
30
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
31
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
32
Azathioprine Approved Phase 4 446-86-6 2265
33
Lenvatinib Approved, Investigational Phase 4 417716-92-8 9823820
34
Coal tar Approved Phase 4 8007-45-2
35
Esketamine Approved, Investigational Phase 4 33643-46-8 182137
36
Meperidine Approved Phase 4 57-42-1 4058
37
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
38
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
39
Molgramostim Investigational Phase 4 99283-10-0
40
Thymalfasin Investigational Phase 4 62304-98-7 16167214 16130571
41
Zuretinol acetate Investigational Phase 4 127-47-9, 29584-22-3 10245972
42
Cadexomer iodine Experimental Phase 4 94820-09-4
43
Adefovir Investigational Phase 4 106941-25-7
44
Clevudine Investigational Phase 4 163252-36-6
45
Tenofovir Experimental, Investigational Phase 4 147127-20-6, 202138-50-9 464205 6398764
46 Immunologic Factors Phase 4
47 Vasodilator Agents Phase 4
48 Adjuvants, Immunologic Phase 4
49 Fibrin Tissue Adhesive Phase 4
50 Anti-Anxiety Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 3357)
# Name Status NCT ID Phase Drugs
1 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related Hepatocellular Carcinoma With Low HBV DNA Replication: Effectiveness and Safety. A Prospective and Randomized Clinical Trial Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
2 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (Viread(R)) in Preventing Hepatocellular Carcinoma Recurrence in Chronic Hepatitis B Virus Infected Patients With Low Viral Load at Baseline Treated With Radiofrequency Ablation or Resection Unknown status NCT02308319 Phase 4 Tenofovir disoproxil fumarate
3 Post-hepatectomy Adjuvant Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Preoperative CTC Level ≥2: a Multicenter Randomized Controlled Trial in China Unknown status NCT02631499 Phase 4 Epirubicin;lipiodol
4 Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
5 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
6 Transcatheter Arterial Chemoembolization as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
7 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
8 A Prospective Randomized Control Study of Cidan Capsule Combined With Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
9 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
10 A Randomized Controled Trial of Oral S-1 in Combination With Sequential Hepatic Arterial Infusion of Oxaliplatin After Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma Unknown status NCT01997957 Phase 4 S-1
11 Hepatic Resection Versus Transarterial Chemoembolization as the Initial Treatment for Resectable Hepatocellular Carcinoma Beyond Milan Criteria Unknown status NCT02138981 Phase 4
12 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
13 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
14 A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection Unknown status NCT03253250 Phase 4 ETV;TDF;ADV;Peginterferon Alfa-2a
15 Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma After Initial Partial Hepatectomy: A Multicenter Experience Unknown status NCT02535117 Phase 4
16 Randomized, Open Label, Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE Therapy in Hepatocellular Carcinoma Unknown status NCT02504983 Phase 4 sorafenib
17 The Observation Of Safety And Survival Of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Combined With Anti-hepatitis B Virus Therapy Unknown status NCT01102335 Phase 4 Telbivudine
18 Effect of Babaodan in Preventing Tumor Recurrence After Hepatectomy for Hepatocellular Carcinoma: a Multicenter, Randomized, Placebo-controlled, Double-blind Trial Unknown status NCT03515369 Phase 4 Babaodan oral capsule;Placebo oral capsule
19 Comparison of Efficacy Between Sorafenib Monotherapy vs. Transarterial Chemoembolization -Sorafenib Sequential Therapy in Hepatocellular Carcinoma Patients With Extrahepatic Metastasis Unknown status NCT03518502 Phase 4 Sorafenib
20 A Prospective Clinical Trial of TACE Combined With Methylcantharidimide Tablets in the Treatment of Large and Unresectable Hepatocellular Carcinoma Unknown status NCT03996681 Phase 4 methylcantharidimide tablets
21 Prophylactic Administration of Antibiotics Before Radiofrequency Ablation for Hepatocellular Carcinoma: A Randomized Trial Unknown status NCT02534961 Phase 4 Cefazolin
22 Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy: A Multicenter Randomized Controlled Trial Unknown status NCT02399033 Phase 4 Xihuang Capsules
23 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis.A Prospective and Randomized Clinical Trial Unknown status NCT01350206 Phase 4
24 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
25 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Relapse and Metastasis of Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
26 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
27 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
28 Investigator Initiated Study of Thymosin in HBV-related HCC Unknown status NCT02281266 Phase 4 thymalfasin;nucleoside analog (suggest to use entecavir)
29 Phase4, to Assess Time to Progression (TTP) and Safety Profile of Doxorubicin-Eluting-Bead Embolization(DEBDOX) in Patients With Advanced HCC Unknown status NCT02525380 Phase 4
30 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
31 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
32 Radiofrequency Ablation vs. Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm.A Prospective and Randomized Clinical Trial Unknown status NCT01351194 Phase 4
33 An Randomized and Controlled Study of Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE Unknown status NCT02557503 Phase 4 Oxaliplatin and fluorouracil
34 Clinical Trial of Cinobufacini Combined With Transarterial Chemoembolization (TACE) on Primary Liver Cancer Unknown status NCT03843229 Phase 4 Cinobufacini injection;cinobufacini tablet
35 A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection. Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
36 Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
37 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
38 A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
39 TAC vs TACE Plus folfox4 as the Treatment of Unresectalbe Liver Metastasis of Colorectal Cancer With Resection of the Primary Tumor: a Prospective, Randomized, Control Trial Unknown status NCT00868569 Phase 4
40 Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
41 A Prospective, Randomized, One-center Study Assessing Overall Survival Using RFA Plus Chemotherapy ± Target Therapy and Chemotherapy ± Target Therapy Alone in Patients With Unresectable Unresectable Colorectal Cancer Liver Metastases Unknown status NCT03127072 Phase 4 chemotherapy ± target therapy
42 Effect of Preoperative Administration of Oral Pregabalin on the Postoperative Analgesia in Patients Scheduled for Radiofrequency Ablationof Focal Lesions in the Liver Unknown status NCT03151213 Phase 4 Pregabalin 150mg
43 A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol Unknown status NCT00567216 Phase 4 Nadolol
44 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With HCC:a Randomized Trial Unknown status NCT01298284 Phase 4 propranolol
45 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
46 Transarterial Chemoembolization Versus Best Support for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Completed NCT00646100 Phase 4
47 Clinical Research of in the Treatment of Unresectable Hepatocellular Carcinoma Completed NCT00829465 Phase 4 Licartin
48 Efficacy of Preoperative Transarterial Chemoembolization for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Prospective Non-Randomized Comparative Study Completed NCT01952353 Phase 4
49 Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Completed NCT03007212 Phase 4
50 Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma Completed NCT00375661 Phase 4 interferon-alfa-2b and ribavirin

Search NIH Clinical Center for Hepatocellular Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
regorafenib
sorafenib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatocellular Carcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: liver neoplasms

Genetic Tests for Hepatocellular Carcinoma

Genetic tests related to Hepatocellular Carcinoma:

# Genetic test Affiliating Genes
1 Hepatocellular Carcinoma 28 APC AXIN1 CASP8 CTNNB1 IGF2R MET PDGFRL PIK3CA TP53

Anatomical Context for Hepatocellular Carcinoma

Organs/tissues related to Hepatocellular Carcinoma:

FMA: Liver, Liver
MalaCards : Liver, T Cells, Bone Marrow, Myeloid, Skin, Lung, Colon

Publications for Hepatocellular Carcinoma

Articles related to Hepatocellular Carcinoma:

(show top 50) (show all 54579)
# Title Authors PMID Year
1
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 53 57 5
15608678 2005
2
MicroRNA expression, survival, and response to interferon in liver cancer. 62 46 57
19812400 2009
3
Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. 53 62 5
10435629 1999
4
Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. 53 62 57
7892276 1995
5
Inducing and exploiting vulnerabilities for the treatment of liver cancer. 62 57
31578521 2019
6
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. 62 57
30814741 2019
7
Necroptosis microenvironment directs lineage commitment in liver cancer. 62 57
30209397 2018
8
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. 62 5
28677271 2017
9
Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. 62 57
24578576 2014
10
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 62 57
23758232 2013
11
Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. 62 57
22922871 2012
12
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. 62 57
21822264 2011
13
Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. 62 57
21499248 2011
14
Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. 62 57
20676096 2010
15
Diet-induced hepatocellular carcinoma in genetically predisposed mice. 62 57
19454484 2009
16
MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. 53 62 46
19490101 2009
17
miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. 53 62 46
19006648 2009
18
Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. 62 57
19221438 2009
19
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. 62 57
18167406 2008
20
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 53 62 46
17616664 2007
21
Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. 62 5
15004724 2004
22
Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. 62 57
12668613 2003
23
Molecular pathogenesis of human hepatocellular carcinoma. 62 57
12149612 2002
24
Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. 53 57
10779553 2000
25
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. 53 5
10700176 2000
26
Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. 62 57
9589695 1998
27
Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. 62 5
1672732 1991
28
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. 53 5
1849234 1991
29
Loss of heterozygosity suggests tumor suppressor gene responsible for primary hepatocellular carcinoma. 62 57
2573067 1989
30
Regional mapping to 4q32.1 by in situ hybridization of a DNA domain rearranged in human liver cancer. 62 57
2847975 1988
31
Deletion in chromosome 11p associated with a hepatitis B integration site in hepatocellular carcinoma. 62 57
2996131 1985
32
Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations. 5
34496175 2021
33
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
34
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity. 5
26266985 2015
35
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. 5
26266975 2015
36
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
37
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 57
24047070 2013
38
Acquired resistance to crizotinib from a mutation in CD74-ROS1. 57
24047073 2013
39
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 57
24047069 2013
40
Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. 57
24047071 2013
41
Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. 5
23100325 2013
42
Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. 5
23000435 2013
43
Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. 5
22658544 2012
44
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. 5
22729222 2012
45
hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. 62 46
20924108 2010
46
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. 62 46
20842113 2010
47
Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. 62 46
20188135 2010
48
miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. 62 46
19843643 2010
49
Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. 62 46
20041405 2010
50
MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. 62 46
20103675 2010

Variations for Hepatocellular Carcinoma

ClinVar genetic disease variations for Hepatocellular Carcinoma:

5 (show top 50) (show all 606)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SET NM_003011.4(SET):c.701A>G (p.Glu234Gly) SNV Other
438787 rs768759521 GRCh37: 9:131456212-131456212
GRCh38: 9:128693933-128693933
2 VDR NM_000376.3(VDR):c.1056T>C (p.Ile352=) SNV Likely Risk Allele
308877 rs731236 GRCh37: 12:48238757-48238757
GRCh38: 12:47844974-47844974
3 VDR NM_000376.3(VDR):c.1024+283G>A SNV Likely Risk Allele
1259287 GRCh37: 12:48239835-48239835
GRCh38: 12:47846052-47846052
4 PDGFRL PDGRL, 2-BP DEL DEL Pathogenic
5469 GRCh37:
GRCh38:
5 CTNNB1 NM_001904.4(CTNNB1):c.283C>T (p.Arg95Ter) SNV Pathogenic
265443 rs775104326 GRCh37: 3:41266486-41266486
GRCh38: 3:41224995-41224995
6 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr) SNV Pathogenic
Likely Pathogenic
39705 rs121913281 GRCh37: 3:178952084-178952084
GRCh38: 3:179234296-179234296
7 CTNNB1 NM_001904.4(CTNNB1):c.1041_1044del (p.Val349fs) DEL Pathogenic
801961 rs1575320216 GRCh37: 3:41268801-41268804
GRCh38: 3:41227310-41227313
8 CTNNB1 NM_001904.4(CTNNB1):c.1494dup (p.His499fs) DUP Pathogenic
499655 rs1553631896 GRCh37: 3:41275327-41275328
GRCh38: 3:41233836-41233837
9 AXIN1 NM_003502.4(AXIN1):c.1085_1116del (p.Val362fs) DEL Pathogenic
6037 rs587776627 GRCh37: 16:359973-360004
GRCh38: 16:309973-310004
10 CASP8 NM_001372051.1(CASP8):c.1228_1229del (p.Val410fs) MICROSAT Pathogenic
7761 rs587776665 GRCh37: 2:202149961-202149962
GRCh38: 2:201285238-201285239
11 IGF2R NM_000876.4(IGF2R):c.4346G>T (p.Gly1449Val) SNV Pathogenic
14795 rs121434587 GRCh37: 6:160490993-160490993
GRCh38: 6:160069961-160069961
12 IGF2R NM_000876.4(IGF2R):c.4391G>A (p.Gly1464Glu) SNV Pathogenic
14796 rs121434588 GRCh37: 6:160491038-160491038
GRCh38: 6:160070006-160070006
13 TP53 NM_000546.6(TP53):c.380C>T (p.Ser127Phe) SNV Pathogenic
182928 rs730881999 GRCh37: 17:7578550-7578550
GRCh38: 17:7675232-7675232
14 LOC109504725, AR NM_000044.6(AR):c.171GCA[20] (p.Gln78_Gln80del) MICROSAT Pathogenic
210223 rs3032358 GRCh37: X:66765159-66765167
GRCh38: X:67545317-67545325
15 LOC108663993, ATXN1 NM_001128164.2(ATXN1):c.588GCA[12] (p.Gln208del) MICROSAT Pathogenic
210503 rs193922926 GRCh37: 6:16327916-16327918
GRCh38: 6:16327685-16327687
16 LOC108663993, ATXN1 NM_001128164.2(ATXN1):c.633_635del (p.His211del) DEL Pathogenic
210506 rs759132871 GRCh37: 6:16327907-16327909
GRCh38: 6:16327676-16327678
17 LOC108663993, ATXN1 NM_001128164.2(ATXN1):c.588GCA[14] (p.Gln208dup) MICROSAT Pathogenic
218439 rs193922926 GRCh37: 6:16327915-16327916
GRCh38: 6:16327684-16327685
18 USF3 NM_001009899.4(USF3):c.4383GCA[11] (p.Gln1478del) MICROSAT Pathogenic
218482 rs10606566 GRCh37: 3:113376111-113376113
GRCh38: 3:113657264-113657266
19 MAP2K3 NM_145109.3(MAP2K3):c.644T>G (p.Leu215Trp) SNV Pathogenic
218844 rs74575904 GRCh37: 17:21207813-21207813
GRCh38: 17:21304501-21304501
20 AR and overlap with 1 gene(s) NM_000044.6(AR):c.171GCA[25] (p.Gln79_Gln80dup) MICROSAT Pathogenic
290422 rs3032358 GRCh37: X:66765158-66765159
GRCh38: X:67545316-67545317
21 MAPK1 NM_002745.5(MAPK1):c.964G>A (p.Glu322Lys) SNV Pathogenic
376450 rs1057519911 GRCh37: 22:22127164-22127164
GRCh38: 22:21772875-21772875
22 AQP7 NM_001170.3(AQP7):c.700C>A (p.Arg234Ser) SNV Pathogenic
402384 rs139024279 GRCh37: 9:33385690-33385690
GRCh38: 9:33385692-33385692
23 LOC108663996, TBP NM_003194.5(TBP):c.228_229del (p.Gln77fs) DEL Pathogenic
403524 rs1491487452 GRCh37: 6:170871052-170871053
GRCh38: 6:170561964-170561965
24 TP53 NM_000546.6(TP53):c.747G>C (p.Arg249Ser) SNV Pathogenic
406598 rs28934571 GRCh37: 17:7577534-7577534
GRCh38: 17:7674216-7674216
25 LOC109504725, AR NM_000044.6(AR):c.171GCA[19] (p.Gln77_Gln80del) MICROSAT Pathogenic
464796 rs3032358 GRCh37: X:66765159-66765170
GRCh38: X:67545317-67545328
26 AR and overlap with 1 gene(s) NM_000044.6(AR):c.171GCA[26] (p.Gln78_Gln80dup) MICROSAT Pathogenic
464797 GRCh37: X:66765158-66765159
GRCh38: X:67545316-67545317
27 LOC109504725, AR NM_000044.6(AR):c.171GCA[22] (p.Gln80del) MICROSAT Pathogenic
464798 GRCh37: X:66765159-66765161
GRCh38: X:67545317-67545319
28 LOC108663996, TBP NM_003194.5(TBP):c.216_218del (p.Gln95del) DEL Pathogenic
522261 rs71815788 GRCh37: 6:170871038-170871040
GRCh38: 6:170561950-170561952
29 ATXN1 and overlap with 1 gene(s) NM_001128164.2(ATXN1):c.636GCA[16] (p.Gln224_Gln225dup) MICROSAT Pathogenic
522332 rs751421308 GRCh37: 6:16327864-16327865
GRCh38: 6:16327633-16327634
30 APC NM_000038.6(APC):c.1695del (p.Val566fs) DEL Pathogenic
840 rs397514032 GRCh37: 5:112164620-112164620
GRCh38: 5:112828923-112828923
31 TERT NM_198253.3(TERT):c.2004G>C (p.Glu668Asp) SNV Pathogenic
268081 rs1554040964 GRCh37: 5:1279532-1279532
GRCh38: 5:1279417-1279417
32 PIK3CA NM_006218.4(PIK3CA):c.3203dup (p.Asn1068fs) DUP Pathogenic
13658 rs587776802 GRCh37: 3:178952146-178952147
GRCh38: 3:179234358-179234359
33 ARID1A NM_006015.6(ARID1A):c.114GGC[4] (p.Ala45del) MICROSAT Pathogenic
591383 rs587779737 GRCh37: 1:27023008-27023010
GRCh38: 1:26696517-26696519
34 TP53 NM_000546.6(TP53):c.267dup (p.Ser90fs) DUP Pathogenic
634762 rs587783062 GRCh37: 17:7579419-7579420
GRCh38: 17:7676101-7676102
35 TAOK2 NM_016151.4(TAOK2):c.1140GGA[5] (p.Glu392del) MICROSAT Pathogenic
773579 rs368747234 GRCh37: 16:29994531-29994533
GRCh38: 16:29983210-29983212
36 USF3 NM_001009899.4(USF3):c.3047dup (p.Asn1016fs) DUP Pathogenic
805968 rs78597857 GRCh37: 3:113377481-113377482
GRCh38: 3:113658634-113658635
37 AR and overlap with 1 gene(s) NM_000044.6(AR):c.171GCA[27] (p.Gln77_Gln80dup) MICROSAT Pathogenic
1168151 GRCh37: X:66765158-66765159
GRCh38: X:67545316-67545317
38 MAPK1 NM_002745.5(MAPK1):c.5CGG[7] (p.Ala7dup) MICROSAT Pathogenic
1174634 GRCh37: 22:22221708-22221709
GRCh38: 22:21867418-21867419
39 USF3 NM_001009899.4(USF3):c.4383GCA[9] (p.Gln1476_Gln1478del) MICROSAT Pathogenic
1174824 GRCh37: 3:113376111-113376119
GRCh38: 3:113657264-113657272
40 ATXN1 and overlap with 1 gene(s) NM_001128164.2(ATXN1):c.636GCA[15] (p.Gln225dup) MICROSAT Pathogenic
1174970 GRCh37: 6:16327864-16327865
GRCh38: 6:16327633-16327634
41 DSPP NM_014208.3(DSPP):c.3264_3290del (p.Asn1092_Ser1100del) DEL Pathogenic
1181538 GRCh37: 4:88537073-88537099
GRCh38: 4:87615921-87615947
42 DSPP NM_014208.3(DSPP):c.3506_3507insTGACAGCAGCGACAGCAG (p.1152DSS[11]) MICROSAT Pathogenic
1193978 GRCh37: 4:88537306-88537307
GRCh38: 4:87616154-87616155
43 DSPP NM_014208.3(DSPP):c.2036_2053dup (p.Ser679_Ser684dup) DUP Pathogenic
1206200 GRCh37: 4:88535832-88535833
GRCh38: 4:87614680-87614681
44 LOC108663993, ATXN1 NM_001128164.2(ATXN1):c.636GCA[12] (p.Gln224_Gln225del) MICROSAT Pathogenic
1206220 GRCh37: 6:16327865-16327870
GRCh38: 6:16327634-16327639
45 DSPP NM_014208.3(DSPP):c.3461_3462insCGATAGCAGCGACAGCAG (p.1152DSS[11]) MICROSAT Pathogenic
1222757 GRCh37: 4:88537261-88537262
GRCh38: 4:87616109-87616110
46 DSPP NM_014208.3(DSPP):c.3339_3347del (p.1095DSS[8]) DEL Pathogenic
1224948 GRCh37: 4:88537151-88537159
GRCh38: 4:87615999-87616007
47 DSPP NM_014208.3(DSPP):c.2214_2231del (p.Asn739_Ser744del) DEL Pathogenic
1233150 GRCh37: 4:88536014-88536031
GRCh38: 4:87614862-87614879
48 DSPP NM_014208.3(DSPP):c.3102CGATAGCAGTGACAGCAG[2] (p.1032DSS[6]) MICROSAT Pathogenic
1235701 GRCh37: 4:88536902-88536919
GRCh38: 4:87615750-87615767
49 DSPP NM_014208.3(DSPP):c.3069_3086del (p.1017NSSDSS[2]) DEL Pathogenic
1239462 GRCh37: 4:88536869-88536886
GRCh38: 4:87615717-87615734
50 DSPP NM_014208.3(DSPP):c.3339_3419del (p.Asn1122_Ser1148del) DEL Pathogenic
1260466 GRCh37: 4:88537152-88537232
GRCh38: 4:87616000-87616080

UniProtKB/Swiss-Prot genetic disease variations for Hepatocellular Carcinoma:

73 (show all 21)
# Symbol AA change Variation ID SNP ID
1 AXIN1 p.Leu106Arg VAR_015589
2 AXIN1 p.Pro345Leu VAR_015590 rs779951904
3 AXIN1 p.Gly425Ser VAR_015591 rs116350678
4 AXIN1 p.Gly650Ser VAR_015592 rs117208012
5 CDKN3 p.Trp31Arg VAR_013842
6 CDKN3 p.Phe78Leu VAR_013843
7 CDKN3 p.Cys79Tyr VAR_013844
8 CDKN3 p.Asn91Lys VAR_013845 rs760687800
9 CDKN3 p.Asp94Val VAR_013846
10 CDKN3 p.Leu95Phe VAR_013847
11 CDKN3 p.Ile108Val VAR_013848 rs144479038
12 CDKN3 p.Asn187Ser VAR_013849
13 CDKN3 p.Lys195Ile VAR_013850
14 MET p.Thr1173Ile VAR_032490 rs121913675
15 MET p.Lys1244Arg VAR_032492 rs121913677
16 MET p.Met1250Ile VAR_032493 rs121913676
17 MTUS1 p.Gln75Lys VAR_035173 rs61733703
18 MTUS1 p.Ala563Ser VAR_035178
19 MTUS1 p.Asn873His VAR_035180 rs187103704
20 MTUS1 p.Gln1201Arg VAR_035184 rs567116808
21 PIK3CA p.Glu545Ala VAR_026176 rs121913274

Cosmic variations for Hepatocellular Carcinoma:

8 (show top 50) (show all 15388)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97724722 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 55
2 COSM94430614 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 55
3 COSM94436083 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 55
4 COSM94063771 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 55
5 COSM88264637 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 55
6 COSM102741209 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 55
7 COSM131494492 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.1159A>G p.M387V 22:29049340-29049340 55
8 COSM103081572 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 55
9 COSM95977701 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 55
10 COSM102131817 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 55
11 COSM95960776 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 55
12 COSM113317148 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 55
13 COSM99592496 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 55
14 COSM128686611 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.1072T>A p.F358I 19:36891962-36891962 55
15 COSM123358576 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.691C>T p.L231= 4:145885684-145885684 55
16 COSM123949383 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 55
17 COSM101741672 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 55
18 COSM86004822 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 55
19 COSM98561269 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 55
20 COSM142353152 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 55
21 COSM142221290 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 55
22 COSM99854658 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.156G>A p.V52= 19:52002156-52002156 55
23 COSM139729931 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 55
24 COSM141470046 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 55
25 COSM141819438 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 55
26 COSM145038099 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 55
27 COSM91868668 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 55
28 COSM91880764 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.2171-78T>G p.? 19:30534769-30534769 55
29 COSM140721836 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.2998+205G>A p.? 18:25194955-25194955 55
30 COSM131506983 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 55
31 COSM94799980 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 55
32 COSM90582798 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 55
33 COSM87577038 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 55
34 COSM109096265 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.3433G>T p.V1145L 9:106974156-106974156 55
35 COSM104985080 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.298+23785G>T p.? 2:179745718-179745718 55
36 COSM104427909 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.20G>T p.S7I 2:179745718-179745718 55
37 COSM151538615 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.253+23785G>T p.? 2:179745718-179745718 55
38 COSM127708351 ZNF345 liver,NS,carcinoma,hepatocellular carcinoma c.47-856A>T p.? 19:36891962-36891962 55
39 COSM135887725 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1168C>G p.L390V 16:89734008-89734008 55
40 COSM84511025 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 55
41 COSM111609487 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1444C>G p.L482V 16:89734008-89734008 55
42 COSM92353291 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 55
43 COSM130415812 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.950C>T p.T317I 12:133010889-133010889 55
44 COSM88697750 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 55
45 COSM95253159 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 55
46 COSM94505616 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 55
47 COSM89943752 ZMYM4 liver,NS,carcinoma,hepatocellular carcinoma c.86-8201G>T p.? 1:35350724-35350724 55
48 COSM101398456 ZIC2 liver,NS,carcinoma,hepatocellular carcinoma c.-18C>T p.? 13:99982047-99982047 55
49 COSM113521587 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 55
50 COSM94679661 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 55

Copy number variations for Hepatocellular Carcinoma from CNVD:

6 (show top 50) (show all 259)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13772 1 1 34600000 Deletion Hepatocellular carcinoma
2 14513 1 109179833 109180141 Copy number EEIG2 Hepatocellular carcinoma
3 14515 1 109194253 109194520 Copy number HENMT1 Hepatocellular carcinoma
4 16438 1 124300000 247249719 Gain Hepatocellular carcinoma
5 17401 1 142600000 165500000 Amplification Hepatocellular carcinoma
6 17404 1 142600000 207200000 Gain Hepatocellular carcinoma
7 19328 1 149600000 153300000 Gain ADAR Liver carcinoma
8 19329 1 149600000 153300000 Gain C1orf43 Liver carcinoma
9 19330 1 149600000 153300000 Gain HAX1 Liver carcinoma
10 19331 1 149600000 163800000 Gain Hepatocellular carcinoma
11 20083 1 15300000 184000000 Gain TAGLN2 Hepatocellular carcinoma
12 20610 1 153300000 154800000 Gain CCT3 Liver carcinoma
13 20847 1 154800000 157300000 Gain CD1C Liver carcinoma
14 20883 1 155000000 165500000 Amplification Hepatocellular carcinoma
15 21205 1 157300000 158800000 Gain NCSTN Liver carcinoma
16 21983 1 163800000 165500000 Gain Hepatocellular carcinoma
17 22134 1 165500000 185800000 Amplification Hepatocellular carcinoma
18 23681 1 172900000 185800000 Amplification Hepatocellular carcinoma
19 25105 1 184000000 212100000 Loss PTPRC Hepatocellular carcinoma
20 25628 1 192100000 197500000 Gain CFHR2 Liver carcinoma
21 26151 1 197500000 205300000 Gain Hepatocellular carcinoma
22 26278 1 198700000 214500000 Amplification Hepatocellular carcinoma
23 26283 1 198700000 249250621 Gain Hepatocellular carcinoma
24 28499 1 222700000 225100000 Gain PYCR2 Liver carcinoma
25 29827 1 236600000 243700000 Amplification Hepatocellular carcinoma
26 29867 1 237459374 237459731 Copy number RYR2 Hepatocellular carcinoma
27 32947 1 40710846 40711321 Copy number Hepatocellular carcinoma
28 33594 1 46500000 60900000 Loss TGFBR3 Hepatocellular carcinoma
29 33953 1 50700000 61300000 Deletion Hepatocellular carcinoma
30 34470 8 101232014 101235406 Copy number POLR2K Liver carcinoma
31 35820 1 67790665 67791040 Copy number IL12RB2 Hepatocellular carcinoma
32 35832 1 67906093 67906510 Copy number Hepatocellular carcinoma
33 36108 1 7200000 16200000 Copy number MTOR Hepatocellular carcinoma
34 37059 1 84900000 117800000 Deletion Hepatocellular carcinoma
35 38186 10 1 6700000 Gain AKR1C3 Hepatocellular carcinoma
36 38902 10 105800000 135534747 Amplification Hepatocellular carcinoma
37 39998 10 12300000 17300000 Loss MRC1 Hepatocellular carcinoma
38 42451 10 34400000 38000000 Amplification CCNY Hepatocellular carcinoma
39 42452 10 34400000 38000000 Amplification CREM Hepatocellular carcinoma
40 42453 10 34400000 38000000 Amplification CUL2 Hepatocellular carcinoma
41 42454 10 34400000 38000000 Amplification GJD4 Hepatocellular carcinoma
42 42455 10 34400000 38000000 Amplification FZD8 Hepatocellular carcinoma
43 42456 10 34400000 38000000 Amplification PARD3 Hepatocellular carcinoma
44 42799 10 40200000 42300000 Deletion Hepatocellular carcinoma
45 48325 11 1 21700000 Amplification Hepatocellular carcinoma
46 48353 11 1 2800000 Copy number IGF2 Hepatocellular carcinoma
47 49881 11 111568063 111568201 Copy number SIK2 Hepatocellular carcinoma
48 50022 11 112800000 127400000 Loss SORL1 Hepatocellular carcinoma
49 57131 11 63100000 76700000 Loss ESRRA Hepatocellular carcinoma
50 57452 11 63400000 77100000 Deletion Hepatocellular carcinoma

Expression for Hepatocellular Carcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Hepatocellular Carcinoma patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 EIF3H eukaryotic translation initiation factor 3 subunit H Liver + 4.39 0.000
2 C9 complement C9 Liver - 4.36 0.000
3 UBD ubiquitin D Liver + 3.39 0.000
4 PSMD6 proteasome 26S subunit, non-ATPase 6 Liver + 3.23 0.000
Search GEO for disease gene expression data for Hepatocellular Carcinoma.

Pathways for Hepatocellular Carcinoma

Pathways related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 34)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.76 PIK3CA CTNNB1 CASP8 AXIN1 APC
2
Show member pathways
12.73 APC AXIN1 CTNNB1 MIR18A TP53
3
Show member pathways
12.59 TP53 PIK3CA CTNNB1 CASP8 AXIN1 APC
4
Show member pathways
12.53 CASP8 IGF2R MET PIK3CA TERT TP53
5 12.41 TP53 TERT PIK3CA MET CTNNB1 AXIN1
6
Show member pathways
12.4 TP53 PIK3CA CTNNB1 CASP8
7
Show member pathways
12.38 TP53 PIK3CA MET CTNNB1
8 12.35 TP53 CTNNB1 AXIN1 APC
9
Show member pathways
12.34 TP53 PIK3CA CTNNB1 AXIN1 APC
10
Show member pathways
12.26 TP53 PIK3CA MET IGF2R CTNNB1 CASP8
11
Show member pathways
12.14 TP53 PIK3CA MET IGF2R
12 12.01 CTNNB1 CASP8 AXIN1 APC
13 11.94 APC AXIN1 IGF2R MET TP53
14 11.82 TP53 PIK3CA CASP8
15
Show member pathways
11.8 CTNNB1 AXIN1 APC
16 11.74 TP53 PIK3CA CTNNB1
17 11.73 TP53 PIK3CA CTNNB1 AXIN1 APC
18
Show member pathways
11.71 TP53 PIK3CA IGF2R
19
Show member pathways
11.7 MIR221 MIR17 MIR155
20 11.64 TERT CTNNB1 APC
21 11.61 PIK3CA MET CTNNB1 APC
22 11.59 CTNNB1 AXIN1 APC
23
Show member pathways
11.54 TP53 PIK3CA APC
24 11.53 MIR21 MIR200B MIR155 MIR122
25 11.51 TP53 MIR34A MIR155
26 11.46 TP53 CTNNB1 CASP8
27 11.43 MIR34A MIR21 MIR200B
28 11.41 CTNNB1 AXIN1 APC
29 11.22 TP53 TERT PIK3CA CTNNB1 CASP8
30 11.19 PIK3CA CTNNB1 AXIN1
31
Show member pathways
11.16 CTNNB1 AXIN1 APC
32 10.9 MET CTNNB1 AXIN1 APC
33 10.86 CTNNB1 AXIN1 APC
34 10.85 TP53 MIR221 MIR21 MIR18A MIR17

GO Terms for Hepatocellular Carcinoma

Cellular components related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Wnt signalosome GO:1990909 9.73 CTNNB1 AXIN1 APC
2 beta-catenin destruction complex GO:0030877 9.63 CTNNB1 AXIN1 APC
3 RISC complex GO:0016442 9.53 MIR224 MIR221 MIR21 MIR200B MIR18A MIR17
4 extracellular vesicle GO:1903561 9.35 MIR34A MIR221 MIR21 MIR17 MIR122

Biological processes related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.16 TP53 TERT MIR221 MIR21 MIR200B CTNNB1
2 miRNA-mediated gene silencing GO:0035195 10.16 MIR34A MIR224 MIR221 MIR21 MIR200B MIR18A
3 cellular response to hypoxia GO:0071456 10.02 TP53 TERT MIR34A MIR17
4 positive regulation of protein kinase B signaling GO:0051897 10 PIK3CA MIR221 MIR21 MET
5 negative regulation of angiogenesis GO:0016525 9.89 MIR34A MIR21 MIR200B CTNNB1
6 negative regulation of miRNA maturation GO:1903799 9.88 TP53 TERT
7 positive regulation of epithelial to mesenchymal transition GO:0010718 9.88 MIR221 MIR21 CTNNB1
8 positive regulation of apoptotic process GO:0043065 9.77 TP53 MIR221 MIR21 MIR200B IGF2R CTNNB1
9 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.73 TERT MIR221 MIR21
10 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 9.72 TERT MIR221 MIR21 MIR17
11 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.71 TP53 MIR34A MIR17
12 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.69 MET MIR21
13 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.67 MIR17 MIR200B MIR21 MIR221
14 negative regulation of vascular wound healing GO:0061044 9.57 MIR34A MIR200B
15 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.56 MIR21 MIR17
16 positive regulation of metalloendopeptidase activity GO:1904685 9.54 MIR21 MIR17
17 negative regulation of interleukin-21 production GO:0032705 9.48 MIR221 MIR21
18 negative regulation of sprouting angiogenesis GO:1903671 9.46 MIR17 MIR18A MIR221 MIR34A
19 negative regulation of gene expression GO:0010629 9.44 TP53 TERT PIK3CA MIR34A MIR21 MIR200B

Molecular functions related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.56 TP53 MIR34A MIR224 MIR21 MIR200B MIR17
2 mRNA base-pairing translational repressor activity GO:1903231 9.23 MIR34A MIR224 MIR221 MIR21 MIR200B MIR18A

Sources for Hepatocellular Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....